186家单位联手，江苏难治复发白血病诊疗协作组在中大医院成立

Core Insights - The establishment of the Jiangsu Province Refractory Relapsed Leukemia Diagnosis and Treatment Collaboration Group aims to address the challenges faced by patients with difficult-to-treat leukemia, particularly in terms of access to effective medical resources and treatment options [2][3][7] - The collaboration involves 186 medical institutions, including top-tier hospitals and various healthcare facilities, to create a comprehensive platform for precise diagnosis, management, and the introduction of new drugs and technologies [2][3][6] Group 1: Medical Resource Distribution - Only 30% of local hospitals in China can provide standardized treatment for refractory relapsed leukemia, forcing approximately 80% of patients to seek care outside their regions [1] - The collaboration group is designed to improve the distribution of medical resources and enhance the treatment capabilities for severe and complex cases of leukemia [3][6] Group 2: Technological Innovation - The blood department at Southeast University Affiliated Zhongda Hospital has developed a key gene panel detection technology for acute leukemia, which has significant clinical value and has won awards for its innovation [4][5] - The team has created personalized treatment plans, particularly excelling in the integration of traditional Chinese and Western medicine for acute myeloid leukemia [4][5] Group 3: Collaborative Platforms - The collaboration group will establish eight platforms focusing on various aspects such as precise diagnosis, traditional and modern treatment integration, technological innovation, telemedicine, and training for medical personnel [6][7] - The initiative aims to leverage big data and artificial intelligence to support individualized treatment and plans to achieve comprehensive coverage of leukemia treatment services across the province within three years [7]